Xcout Intel
Nob Hill Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Nob Hill Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Nob Hill Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Nob Hill Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Nob Hill Therapeutics, Inc.
Nob Hill Therapeutics, Inc. is a Delaware corporation headquartered in Albuquerque, New Mexico. The company specializes in creating innovative inhalation therapies, including the development of DryNeb, a first-in-kind dry powder product to improve lung treatments.
Nob Hill Therapeutics, Inc. at a glance
Nob Hill Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series A, raised $1.8M in July 2024. Xcout tracks 8 named people at Nob Hill Therapeutics, Inc., including Noel Greenberger (Chief Executive Officer).
Nob Hill Therapeutics, Inc. leadership
- Noel GreenbergerChief Executive Officer
- Hugh SmythChief Technology Officer
- Matt ReedChief Scientific Officer
- Paul AtkinsExecutive Chairman
- Craig Davies-CuttingHead of R&D
- Calvin GoforthDirector
2 more named people on record for Nob Hill Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Nob Hill Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $1.8M | 3 named | |
| — | $100,000 | 3 named | |
| SEC Form D filing | $50,000 | — | |
| SEC Form D filing | $75,000 | — | |
| SEC Form D filing | $143,545 | — | |
| SEC Form D filing | $250,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Nob Hill Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Nob Hill Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Nobilis Therapeutics, Inc. is a Delaware C-corporation headquartered in Portland, Oregon, focused on the therapeutic uses of inert gas mixtures and portable delivery devices.
Biotech
VERO Biotech Inc. is an emerging biotechnology company focused on the design and delivery of inhaled nitric oxide systems such as GENOSYL, with headquarters located in Georgia.
Similar biotechnology company
Bexson Biomedical is a US-based biopharmaceutical company situated in Santa Barbara, California, focused on the research and development of non-opioid therapeutics and drug delivery systems.
Similar biotechnology company
NovoThelium is a privately held biotechnology startup based in San Antonio, Texas, that is developing a tissue-engineered matrix for nipple regeneration following mastectomies.
Similar biotechnology company
Eyenovia, Inc. is a New York-based ophthalmic technology and pharmaceutical manufacturing company focused on targeted drug-delivery solutions for eye care using its proprietary Optejet device.
Biotech
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Pharmaceuticals
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Similar biotechnology company
AeroRx Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic obstructive pulmonary disease (COPD).
Similar biotechnology company
Sunterra Bio is a biopharmaceutical company focused on developing inhaled small-molecule therapies for rare pulmonary diseases. Headquartered in Carlsbad, California, the company advances targeted treatments for respiratory conditions.
Similar biotechnology company
Altesa BioSciences is a clinical-stage pharmaceutical company headquartered in College Park, Georgia. The company is dedicated to improving the lives of individuals suffering from chronic lung diseases, including conditions such as COPD and asthma.
Biotech
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
Similar biotechnology company
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Nob Hill Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Nob Hill Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →